Adjuvant Oxaliplatin With S-1 vs Adjuvant Oxaliplatin With Capecitabine in Patients With Locally Advanced Gastric Cancer Undergoing D2 Gastrectomy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Perioperative or Postoperative Adjuvant Oxaliplatin With S-1 Versus Adjuvant Oxaliplatin With Capecitabine in Patients With Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy (RESOLVE): An Open-Label, Superiority and Non-Inferiority, Phase 3 Randomised Controlled Trial
Lancet Oncol 2021 Jul 09;[EPub Ahead of Print], X Zhang, H Liang, Z Li, Y Xue, Y Wang, Z Zhou, J Yu, Z Bu, L Chen, Y Du, X Wang, A Wu, G Li, X Su, G Xiao, M Cui, D Wu, L Chen, X Wu, Y Zhou, L Zhang, C Dang, Y He, Z Zhang, Y Sun, Y Li, H Chen, Y Bai, C Qi, P Yu, G Zhu, J Suo, B Jia, L Li, C Huang, F Li, Y Ye, H Xu, X Wang, Y Yuan, JY E, X Ying, C Yao, L Shen, J JiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.